Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the Hong Kong Stock Exchange (HKEX) in anticipation of a public listing. The firm is targeting a minimum capital raise of USD 100 million, aiming for a valuation of at least USD 600 million. This follows Mirxes’ initial filing with HKEX in July 2023.
Mirxes is dedicated to the application of RNA technology to create precise, non-invasive, and cost-effective blood-based miRNA test kits for the early detection of cancer and other diseases. According to the company’s prospectus, it recorded losses of USD 70.4 million in 2023, with research and development expenditures amounting to USD 20.2 million. Despite the losses, Mirxes achieved revenues of USD 24.2 million, marking a 36% year-on-year growth. The company is aiming to complete its Hong Kong IPO within the next six months.- Flcube.com
